Why split Reckitt Benckiser?

Synopsis

Oliver Lex discusses the phrase 'unlock value' in the context of Reckitt Benckiser's decision to split its Pharmaceuticals business. The company confirms this demerger, which will complete by the end of the year, as it spins off one of its pharmaceutical products to investors. Lex expresses skepticism about the potential for value creation from this move, noting that the consumer goods business and the smaller, declining Pharmaceuticals business may not yield a higher market capitalization. The new entity, IND, will focus on an opiate treatment that has faced patent expiration and increased generic competition. Despite some revenue still coming from a reformulated product, Lex highlights the risks involved in research and development and the uncertainty surrounding the new business's future, including potential expansions into treatments for other addictions like cocaine or alcohol.